Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy

INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01447654

Acronym

INHERIT

Enrollment

130

Registered

2011-10-06

Start date

2011-11-30

Completion date

2014-06-30

Last updated

2014-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Cardiomyopathy

Keywords

Hypertrophic cardiomyopathy, Hypertrophic obstructive cardiomyopathy, Hypertrophy, Losartan, Angiotensin II receptor antagonist

Brief summary

Objective The objective of the study is to assess the structural and functional cardiac effects of treatment with losartan in patients with hypertrophic cardiomyopathy (HCM). Design The study is a randomized, placebo-controlled, double-blinded trial. The follow-up period is 12 months. 130 patients with HCM will be included in predefined subgroups. Genotype positive relatives with borderline hypertrophy (\> 13 mm) will also be included. Data on individuals with borderline hypertrophy will be analysed separately from the rest of the cohort. Primary outcome Ventricular hypertrophy assessed as left ventricular mass and maximal wall thickness.

Interventions

DRUGLosartan

100 mg for 12 months.

DRUGPlacebo

100 mg for 12 months.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Hypertrophic cardiomyopathy * \> 18 years * Sinus rhythm

Exclusion criteria

* EF \< 50 % * Treatment with RAS-inhibitor * Contraindications to losartan

Design outcomes

Primary

Measure	Time frame	Description
Hypertrophy of left ventricle	12 months	Left ventricular mass. Maximal wall thickness.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026